REG - Physiomics PLC - Contract Award

PhysiomicsAnnouncement

01/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250701:nRSA0847Pa&default-theme=true

RNS Number : 0847P  Physiomics PLC  01 July 2025

1 July 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Contract Award

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce a new contract award
with an existing client.

In this new project, Physiomics will apply PK/PD modelling and simulation
expertise to support preclinical-to-clinical translation for one of the
client's lead candidates and inform selection of human dosing schemes for a
First in Human clinical trial.

This contract, which supports the development of a non-oncology therapeutic,
highlights the value of Physiomics' integrated modelling and simulation
approach across the drug development lifecycle - from early discovery through
translational planning and into clinical development. The contract is valued
at £98,600 and will be delivered over the next 18 months.

Dr Peter Sargent, CEO of Physiomics, commented:

"We are delighted to continue partnering with this client and announce this
follow on work with their team. Working with them from early discovery through
to clinical planning enables us to add deeper insights into their experimental
and clinical trial design, helping them accelerate this promising drug
development programme."

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTWPUUPQUPAGBU